MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies

Micro-Abstract This study evaluated micro-RNAs expression and outcome in two different cohorts of metastatic colorectal cancer patients treated with cetuximab or panitumumab. High intensity levels of the signature MiR-99a/Let-7c/miR-125b associated with significant longer progression-free survival a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical colorectal cancer 2014-03, Vol.13 (1), p.37-45.e4
Hauptverfasser:	Cappuzzo, Federico, Sacconi, Andrea, Landi, Lorenza, Ludovini, Vienna, Biagioni, Francesca, D'Incecco, Armida, Capodanno, Alessandra, Salvini, Jessica, Corgna, Enrichetta, Cupini, Samanta, Barbara, Cecilia, Fontanini, Gabriella, Crinò, Lucio, Blandino, Giovanni
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - therapeutic use Biomarkers, Tumor - genetics Cetuximab Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - mortality Disease-Free Survival Drug Resistance, Neoplasm - genetics Female Gastroenterology and Hepatology Hematology, Oncology and Palliative Medicine Humans Kaplan-Meier Estimate Let-7c Male MicroRNAs - analysis Middle Aged miR-125b miR-99a Oligonucleotide Array Sequence Analysis Panitumumab Proportional Hazards Models Receptor, Epidermal Growth Factor - antagonists & inhibitors Transcriptome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Micro-Abstract This study evaluated micro-RNAs expression and outcome in two different cohorts of metastatic colorectal cancer patients treated with cetuximab or panitumumab. High intensity levels of the signature MiR-99a/Let-7c/miR-125b associated with significant longer progression-free survival and overall survival in the whole population and in KRAS wild-type patients. MiR-99a/Let-7c/miR-125b signature may improve the selection of KRAS wild-type patients for anti-EGFR therapy.
ISSN:	1533-0028 1938-0674
DOI:	10.1016/j.clcc.2013.11.006